APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND REAFFIRMS FULL YEAR 2023 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:00:21+00:00August 10, 2023|2023 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON AUGUST 10, 2023By ApyxMedical|2025-12-12T19:00:50+00:00June 29, 2023|2023 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) CLEARANCE FOR THE RENUVION MICRO HANDPIECEBy ApyxMedical|2025-12-12T19:01:32+00:00June 14, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:02:02+00:00May 11, 2023|2023 Shareholder News, J-Plasma, Renuvion|
RENUVION RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTIONBy ApyxMedical|2025-12-12T19:02:46+00:00May 2, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURINGBy ApyxMedical|2025-12-12T19:03:25+00:00April 28, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON MAY 11, 2023By ApyxMedical|2025-12-12T19:03:58+00:00April 5, 2023|2023 Shareholder News, J-Plasma, Renuvion|
RENUVION WINS ADDY AWARD FOR #THISISME CAMPAIGNBy ApyxMedical|2025-12-12T19:04:30+00:00March 27, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2023 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:05:09+00:00March 16, 2023|2023 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO COAGULATE AND CONTRACT SOFT TISSUES, INCLUDING SUBCUTANEOUS TISSUE, WHERE NEEDEDBy ApyxMedical|2025-12-12T19:05:39+00:00February 27, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES NEW FIVE-YEAR CREDIT AGREEMENT WITH MIDCAP FINANCIALBy ApyxMedical|2025-12-12T19:06:56+00:00February 21, 2023|2023 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS ON MARCH 16, 2023By ApyxMedical|2025-12-12T19:07:24+00:00February 16, 2023|2023 Shareholder News, J-Plasma, Renuvion|
RENUVION COSMETIC NECK LAXITY PROCEDURE TO BE FEATURED ON ‘THE BALANCING ACT’ TALK SHOW ON LIFETIME FEBRUARY 13By ApyxMedical|2025-12-12T19:07:54+00:00February 9, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF THE RENUVION APR HANDPIECE FOR THE COAGULATION OF SUBCUTANEOUS SOFT TISSUES WHERE NEEDED, FOLLOWING LIPOSUCTIONBy ApyxMedical|2025-12-12T19:08:24+00:00February 1, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION LAUNCHES NEW ‘APYX ONE CONSOLE’ FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATESBy ApyxMedical|2025-12-12T19:10:24+00:00January 25, 2023|2023 Shareholder News, Renuvion|
APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE RESULTSBy ApyxMedical|2025-12-12T19:11:04+00:00January 10, 2023|2023 Shareholder News, J-Plasma, Renuvion|
